Article Type
Changed
Wed, 06/29/2022 - 12:20

Key clinical point: The pediatric hepatocellular carcinoma (HCC) subtypes fibrolamellar carcinoma (FLC) and conventional HCC (cHCC) can be considered nonequivalent entities because they show different anatomic patterns and outcomes together with their known molecular differences.

Major finding: HCC subtypes were significantly different in presentation and behavior, with increased lymph node involvement in FLC and higher stage in cHCC. Multivariate analysis revealed increased mortality in cHCC compared with that in FLC (adjusted hazard ratio 2.2; P = .004).

Study details: These findings are from a multicenter, retrospective review study including 262 patients <20 years of age with hepatocellular neoplasms, including cHCC (n = 110), FLC (n = 119), and tumors with mixed features of HCC and hepatoblastoma (n = 33).

Disclosures: The study was supported by the University of Utah Population Health Research Foundation and National Center for Advancing Translational Sciences of the US National Institutes of Health. Some authors reported receiving research grants or travel support from various sources.

Source: Short SS et al. Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study. Cancer. 2022 (May 13). Doi: 10.1002/cncr.34256

 

Publications
Topics
Sections

Key clinical point: The pediatric hepatocellular carcinoma (HCC) subtypes fibrolamellar carcinoma (FLC) and conventional HCC (cHCC) can be considered nonequivalent entities because they show different anatomic patterns and outcomes together with their known molecular differences.

Major finding: HCC subtypes were significantly different in presentation and behavior, with increased lymph node involvement in FLC and higher stage in cHCC. Multivariate analysis revealed increased mortality in cHCC compared with that in FLC (adjusted hazard ratio 2.2; P = .004).

Study details: These findings are from a multicenter, retrospective review study including 262 patients <20 years of age with hepatocellular neoplasms, including cHCC (n = 110), FLC (n = 119), and tumors with mixed features of HCC and hepatoblastoma (n = 33).

Disclosures: The study was supported by the University of Utah Population Health Research Foundation and National Center for Advancing Translational Sciences of the US National Institutes of Health. Some authors reported receiving research grants or travel support from various sources.

Source: Short SS et al. Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study. Cancer. 2022 (May 13). Doi: 10.1002/cncr.34256

 

Key clinical point: The pediatric hepatocellular carcinoma (HCC) subtypes fibrolamellar carcinoma (FLC) and conventional HCC (cHCC) can be considered nonequivalent entities because they show different anatomic patterns and outcomes together with their known molecular differences.

Major finding: HCC subtypes were significantly different in presentation and behavior, with increased lymph node involvement in FLC and higher stage in cHCC. Multivariate analysis revealed increased mortality in cHCC compared with that in FLC (adjusted hazard ratio 2.2; P = .004).

Study details: These findings are from a multicenter, retrospective review study including 262 patients <20 years of age with hepatocellular neoplasms, including cHCC (n = 110), FLC (n = 119), and tumors with mixed features of HCC and hepatoblastoma (n = 33).

Disclosures: The study was supported by the University of Utah Population Health Research Foundation and National Center for Advancing Translational Sciences of the US National Institutes of Health. Some authors reported receiving research grants or travel support from various sources.

Source: Short SS et al. Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study. Cancer. 2022 (May 13). Doi: 10.1002/cncr.34256

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: HCC July 2022
Gate On Date
Wed, 01/19/2022 - 16:00
Un-Gate On Date
Wed, 01/19/2022 - 16:00
Use ProPublica
CFC Schedule Remove Status
Wed, 01/19/2022 - 16:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
332967.1
Activity ID
83146
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
Exact Sciences Corporate [ 6025 ]